Evanthia Galanis MD

PubMed

• Repurposing the SSRI paroxetine increases lymphocyte mobilization and improves the efficacy of measles virus-based immunovirotherapy.
  Georgios M Stergiopoulos, Susanna C Concilio, Kim B Viker, Susan M Clark, Steven I Robinson
  Molecular Therapy. Oncology. 2026-03-19
• Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial.
  Priscilla K Brastianos, Katharine Dooley, Susan Geyer, Elizabeth R Gerstner, Timothy J Kaufmann
  Nature Medicine. 2026-01-16
• Replication competent La Crosse virus pseudotyped VSV vector system as vaccine and serological diagnostic reagent.
  Ianko Iankov, Arun Ammayappan, Kimberly Viker, Carla Weisend, Matthew Beard
  Virus Research. 2026-01-01

Journal Articles

• Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma  
  Domingo-Musibay E, Allen C, Kurokawa C, Hardcastle JJ, Aderca I, Msaouel P, Bansal A, Jiang H, DeGrado TR, Galanis E, Cancer Gene Ther, 1/14/2014
• New validated prognostic models and prognostic calculators in patients with low grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NC...  
  Gorlia T, Wenting W, Wang M, Baumert B, Mehta M, Buckner JC, Shaw E, Brown P, Stupp R, Galanis E, Lacombe D, van den, Neuro Oncol, 1/1/2013
• Specific targeting of human interleukin (il)-13 receptor alpha 2-positive cells with lentiviral vectors displaying il-13  
  Ou W, Marino MP, Suzuki A, Joshi B, Husain SR, Maisner A, Galanis E, Puri RK, Reiser J, Human Gene Therapy Methods, 1/1/2012

Books/Book Chapters

• Gene and Cell Therapy: Therapeutic Mechanisms and Strategies 
  Chapter: Oncolytic Measles Virus-based delivery systems. 
  Page 157 - 174Msaouel P, Galanis EEditors: N.S. Templeton.CRC Press, Boca RatonEdition 4th,2014
• Oncolytic Viruses: Methods and Protocols 
  Chapter: Oncolytic measles virus retargeting by ligand display. 
  Page 141 - 162Msaouel P, Iankov ID, Allen C, Russell SJ, Galanis EEditors: D.H. Kirn, Ta-Chiang Liu and S.H. Thorne.Humana Press Inc.2012
• Brain Tumors: Practical Guide to Diagnosis and Treatment 
  Chapter: Malignant central nervous system neoplasms of mesenchymal origin. 
  Page 325 - 340Galanis EEditors: Baehring JM, Piepmeier JM.Informa Healthcare, New York2007

Abstracts/Posters

• Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902).
  Evanthia Galanis, MD, 2014 American Society of Clinical Oncology Annual Meeting, Chicago, IL, 1/1/2014
• Gene expression profile of innate immune anti-viral factors in ovarian cancer patients treated with oncolytic measles virus.
  Iankov I, Kurokawa C, Middha S, Aderca I, Allen C, Keeney G, Federspiel M, Maurer M, Atherton P, Kalli K, Hartmann L, Galanis E, Mol Ther, 1/1/2014
• Modulation of innate immunity with ctla4 blockade in measles virotherapy for glioblastoma.
  Hardcastle J, Feng J, Kurokawa C, Domingo-Musibay E, Allen C, Johnson A, Galanis E, Mol Ther, 1/1/2014

Lectures

• Integrating Tumor Genomics Including WHO Guidelines Into Novel Clinical Trial Designs 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• "Measles and Vesicular Stomatitis Virus Strains as Novel Oncolytic Platforms" 
  Barcleona, Spain - 1/1/2014
• "Cooperative Group Update" 
  Miami, FL - 1/1/2014